Alyeska Investment Group, L.P. Metacrine, Inc. Transaction History

Alyeska Investment Group, L.P.

  • $16.5 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021
SELL
$7.75 - $11.42 $11,144 - $16,421
-1,438 Reduced 0.79%
179,782 $1.41 Million
Q3 2020

Nov 16, 2020
BUY
$9.38 - $11.76 $1.7 Million - $2.13 Million
181,220 New
181,220 $1.85 Million

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Metacrine, Inc.

MTCR Quotes by TradingView
  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email